Clinical Trial Update: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for CJNJ-67652000 in combination with prednisone to treat metastatic castration-resistant prostate cancer, including SPOP-mutant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CJNJ-67652000
• PREDNISONE (Prednisone)

Snippet

Sponsor: Mayo Clinic | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING